PL4441028T3 - Sól s-oksprenololu - Google Patents

Sól s-oksprenololu

Info

Publication number
PL4441028T3
PL4441028T3 PL24703833.4T PL24703833T PL4441028T3 PL 4441028 T3 PL4441028 T3 PL 4441028T3 PL 24703833 T PL24703833 T PL 24703833T PL 4441028 T3 PL4441028 T3 PL 4441028T3
Authority
PL
Poland
Prior art keywords
oxprenolol
salt
Prior art date
Application number
PL24703833.4T
Other languages
English (en)
Inventor
Melissa JOSEPH
Ronnie Maxwell Lawrence
Elaine MORTEN
Saurabh CHITRE
Natalie Louise KELK
Craig Callahan
Original Assignee
Actimed Therapeutics Ltd
Faraday Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimed Therapeutics Ltd, Faraday Pharmaceuticals, Inc. filed Critical Actimed Therapeutics Ltd
Publication of PL4441028T3 publication Critical patent/PL4441028T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/32Thermal properties
    • C01P2006/33Phase transition temperatures
    • C01P2006/34Melting temperatures
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL24703833.4T 2023-01-27 2024-01-26 Sól s-oksprenololu PL4441028T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2301180.2A GB202301180D0 (en) 2023-01-27 2023-01-27 Salt of a pharmaceutical compound
PCT/GB2024/050208 WO2024157024A1 (en) 2023-01-27 2024-01-26 Salt of s-oxprenolol

Publications (1)

Publication Number Publication Date
PL4441028T3 true PL4441028T3 (pl) 2025-09-01

Family

ID=85476401

Family Applications (1)

Application Number Title Priority Date Filing Date
PL24703833.4T PL4441028T3 (pl) 2023-01-27 2024-01-26 Sól s-oksprenololu

Country Status (21)

Country Link
US (1) US20250228799A1 (pl)
EP (1) EP4441028B1 (pl)
JP (1) JP2026509088A (pl)
KR (1) KR20250149662A (pl)
CN (1) CN120769844A (pl)
AU (1) AU2024212388A1 (pl)
DK (1) DK4441028T3 (pl)
ES (1) ES3034394T3 (pl)
FI (1) FI4441028T3 (pl)
GB (1) GB202301180D0 (pl)
HR (1) HRP20250842T1 (pl)
HU (1) HUE071923T2 (pl)
IL (1) IL322364A (pl)
LT (1) LT4441028T (pl)
MX (1) MX2025008528A (pl)
PL (1) PL4441028T3 (pl)
PT (1) PT4441028T (pl)
RS (1) RS67013B1 (pl)
SI (1) SI4441028T1 (pl)
SM (1) SMT202500240T1 (pl)
WO (1) WO2024157024A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222169A1 (en) * 2024-04-19 2025-10-23 Faraday Pharmaceuticals, Inc. S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323580A (zh) * 2008-07-25 2008-12-17 河北科技大学 手性芳氧丙醇胺类化合物及其盐的合成方法
WO2014138814A1 (en) 2013-03-14 2014-09-18 Coats Andrew J S S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
WO2014138806A1 (en) 2013-03-14 2014-09-18 Coats Andrew J S Oxprenolol compositions for treating cancer

Also Published As

Publication number Publication date
AU2024212388A1 (en) 2025-07-10
ES3034394T3 (en) 2025-08-18
WO2024157024A1 (en) 2024-08-02
CN120769844A (zh) 2025-10-10
EP4441028B1 (en) 2025-04-23
LT4441028T (lt) 2025-07-10
GB202301180D0 (en) 2023-03-15
EP4441028A1 (en) 2024-10-09
FI4441028T3 (fi) 2025-06-30
IL322364A (en) 2025-09-01
SMT202500240T1 (it) 2025-09-12
HRP20250842T1 (hr) 2025-09-12
MX2025008528A (es) 2025-11-03
RS67013B1 (sr) 2025-08-29
DK4441028T3 (da) 2025-06-30
KR20250149662A (ko) 2025-10-16
PT4441028T (pt) 2025-06-26
HUE071923T2 (hu) 2025-10-28
US20250228799A1 (en) 2025-07-17
JP2026509088A (ja) 2026-03-17
SI4441028T1 (sl) 2025-08-29

Similar Documents

Publication Publication Date Title
HUE061482T2 (hu) Szintézismódszer
PT4058151T (pt) Novo sal de composto de terfenilo
IL304402A (en) A useful morph form of the at-527 hemisulfate salt
ES3059247T3 (en) Inhibitors of sarm1
IL312564A (en) Polymorphs of the hydrochloride salt of linfarezan glurate
IL320297A (en) Salt forms of IRAK4 joints
PL4313945T3 (pl) Krystaliczny bromowodorek 5-meo-dmt
GB202411655D0 (en) Application of circHIF1a
KR102423280B9 (ko) Sot-mram 면적 최적화 기법
GB202204778D0 (en) Novel crystalline salt forms of mesembrine
GB202103774D0 (en) Detectiion of Ransomware
HUE072981T2 (hu) Azakinolinok mint CD38 gátlók
LT4441028T (lt) S-oksprenololio druska
GB202207709D0 (en) 5-chiloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt
GB202110403D0 (en) Ulodesine Salt
IL304419A (en) salt crystals
IL317645A (en) Methods for preparing tolbrutinib
GB201903055D0 (en) Method of oligonucleaotide synthesis
IL277578A (en) New salt forms of URAT-1 inhibitors
GB2603328B (en) Process for the synthesis of elagolix sodium salt and intermediates of said process
GB202316444D0 (en) Salts of opicapone
CA3277900A1 (en) Salt of s-oxprenolol
CA3300217A1 (en) Polymorph of ribociclib salt
GB202215264D0 (en) Use of urolithins
GB202104272D0 (en) Salt